Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

NCT04359784 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
27
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fred Hutchinson Cancer Center

Collaborators